Terns Pharma Rg

Clinical‑stage biotech in Foster City developing orally‑administered small‑molecule oncology and obesity/metabolism therapies: TERN‑701 (Phase I BCR‑ABL TKI for CML), TERN‑601 (Phase I GLP‑1R agonist for obesity), and TERN‑500/800 GIPR modulators in trials.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 59
HQ: Foster City

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
TERN	Terns Pharma Rg Cap: 3.9B	EQUITY	NMS	USD	US8808811074	Active	📈